
													
															
															Year
															DEALS // DEV.
															Country
															
															Therapeutic Area
															Study Phase
															Deal Type
															Product Type
															Dosage Form
															Lead Product
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tibolone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : BIOSYENT PHARMA INC
Deal Size : Undisclosed
Deal Type : Acquisition
BioSyent Announces Agreement to Purchase Tibelia® (tibolone) Assets
Details : BioSyent has acquired intellectual property, global rights, certain licensing, distribution and supply agreements related to Tibelia (tibolone), a prescription hormone replacement therapy.
Product Name : Tibelia
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 20, 2024
Lead Product(s) : Tibolone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : BIOSYENT PHARMA INC
Deal Size : Undisclosed
Deal Type : Acquisition

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Estetrol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Caring Cross and ImmunoACT Ink Agreement to Commercialize TriCAR-T Immunotherapy
Details : Donesta (estetrol) is a next generation orally administered Estetrol (E4)-based hormone therapy product, which is under phase 3 clinical development for the treatment of the symptoms of menopause.
Product Name : Donesta
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 29, 2024
Lead Product(s) : Estetrol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Estetrol,Drospirenone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients
Details : Estelle (estetrol monohydrate) is an estrogen receptor agonist small molecule drug candidate, which is currently being evaluated in combination with drospirenone for contraception for 12 to 17 years aged females.
Product Name : Estelle
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 20, 2023
Lead Product(s) : Estetrol,Drospirenone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Estetrol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial
Details : Donesta (estetrol) is a next generation orally administered Estetrol (E4)-based hormone therapy product, which is under phase 3 clinical development for the treatment of the symptoms of menopause.
Product Name : Donesta
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 18, 2023
Lead Product(s) : Estetrol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Estetrol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Donesta (estetrol) is a hormone capsule formulation acting as an Estrogen receptor agonist, approved for the treatment of alleviating symptoms of menopause.
Product Name : Donesta
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 30, 2023
Lead Product(s) : Estetrol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Estetrol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : SEARCHLIGHT PHARMA
Deal Size : $17.9 million
Deal Type : Licensing Agreement
Mithra and Searchlight Pharma Sign DONESTA® Licensing Agreement for Canada
Details : Under the terms of the agreement, Searchlight will have sales and marketing rights for DONESTA® in Canada. DONESTA (estetrol) phase 3 clinical program, which demonstrated a meaningful reduction in the frequency and severity of vasomotor symptoms compare...
Product Name : Donesta
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 26, 2023
Lead Product(s) : Estetrol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : SEARCHLIGHT PHARMA
Deal Size : $17.9 million
Deal Type : Licensing Agreement

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Estetrol,Drospirenone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Fuji Pharma
Deal Size : $45.4 million
Deal Type : Licensing Agreement
Details : Under the agreements, Fuji Pharma obtains the rights to commercialize and advance the develoopment of Estelle, Mithra’s oral contraceptive product candidate based on Estetrol, for the treatment of Japanese patients with dysmenorrhea or endometriosis, i...
Product Name : Estelle
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 23, 2023
Lead Product(s) : Estetrol,Drospirenone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Fuji Pharma
Deal Size : $45.4 million
Deal Type : Licensing Agreement

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Estetrol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : H.C. Wainwright & Co
Deal Size : $70.1 million
Deal Type : Private Placement
Mithra Prices Private Placement to Raise EUR 20 Million in Equity
Details : The proceeds will support the NDA filing of Donesta, a next generation Estetrol-based hormone therapy, and to support differentiation for treatment of menopause symptoms related to hair, skin and sexual desire, and for the development of Estetrol and Zor...
Product Name : Donesta
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 24, 2023
Lead Product(s) : Estetrol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : H.C. Wainwright & Co
Deal Size : $70.1 million
Deal Type : Private Placement

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Estetrol,Drospirenone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Fuji Pharma
Deal Size : $45.4 million
Deal Type : Licensing Agreement
Details : Under the agreements, Fuji Pharma obtains the rights to commercialize and advance the develoopment of Estelle, Mithra’s oral contraceptive product candidate based on Estetrol, for the treatment of Japanese patients with dysmenorrhea or endometriosis, i...
Product Name : Estelle
Product Type : Miscellaneous
Upfront Cash : $29.0 million
August 03, 2023
Lead Product(s) : Estetrol,Drospirenone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Fuji Pharma
Deal Size : $45.4 million
Deal Type : Licensing Agreement

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Estetrol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : SEARCHLIGHT PHARMA
Deal Size : $18.7 million
Deal Type : Licensing Agreement
Mithra and Searchlight Pharma Announce Donesta® Licensing Agreement for Canada
Details : Under the agreement, Searchlight will have the Canadian rights to Donesta, a next generation orally administered Estetrol (E4)-based hormone therapy product, for the treatment of the symptoms of menopause.
Product Name : Donesta
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 31, 2023
Lead Product(s) : Estetrol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : SEARCHLIGHT PHARMA
Deal Size : $18.7 million
Deal Type : Licensing Agreement
